FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL       |           |  |  |  |  |  |  |  |  |  |  |
|--------------------|-----------|--|--|--|--|--|--|--|--|--|--|
| OMB Number:        | 3235-0287 |  |  |  |  |  |  |  |  |  |  |
| Estimated average  | burden    |  |  |  |  |  |  |  |  |  |  |
| hours per response | e: 0.5    |  |  |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Klompas Neil A</u> |  |  | 2. Issuer Name <b>and</b> Ticker or Trading Symbol Zymeworks Inc. [ ZYME ] |  |   |          |  |   |                 |  | Check                        | all app   |                              |   | 10% O  |  |  |  |
|--|--|--|--|--|---|----------|--|---|-----------------|--|------------------------------|---|------------------------------|---|--|--|--|--|
|  | (Fir<br>MEWORKS  | ,  | Aiddle)  | 3. Date of Earliest Transaction 12/09/2020 |   |          |  |   | on (Mon         | nth/Day/Year)  |                              |   | X                            | below   | Officer (give title below)  Chief Financial Off  |  |  | эреспу   |
| (Street)   | UVER A1  | · V  | 76H 3V9  |  | 4. If Amendment, Date of Original Filed (Month/Day/Year) 12/11/2020 |          |  |   |                 |  |                              |   | 3. Indiv<br>_ine)<br>X       | vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person |  |  |  |  |
|  | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   |  |  |  |   |          |  |   |                 |  |                              |   |                              |   |  |  |  |  |
| Date   |  |  | 2. Transaction<br>Date<br>(Month/Day/Yo                                    | Execution D                                |   | on Date, |  | 3.<br>Transaction<br>Code (Instr.<br>8) |                 | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 an |                              |   | nd 5) Secur<br>Benef<br>Owne |   | icially<br>d Following   | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I) |  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership                |
|  |  |  |  |  |   |          | 7  | Code                                    | v               | Amount   | (A) or<br>(D)                | Price   |                              | Reported Transaction(s) (Instr. 3 and 4)  |  | (Instr. 4)   |  | (Instr. 4)   |
| Common Shares 12/09/2020                                       |  |  |  | .0   |   |          |  | М                                       |                 | 8,380  | A                            | \$4.19  | 45 <sup>(1)</sup>            | 17,492(4)   |  | D  |  |  |
| Common Shares 12/09/202  |  |  | .0   | ,  |   |          | M  |   | 16,620          | A  | \$5.67                       | .6708(2)  |                              | 34,112(4)   |  |  |  |  |
| Common Shares 12/09/20   |  |  | 12/09/202  | 0  |   |          | S  |   | 25,000          | D \$53.24  |                              | 53(3)   | 9,112(4)                     |   | D  |  |  |  |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |  |  |   |          |  |   |                 |  |                              |   |                              |   |  |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)            | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year)                |  | Transaction Code (Instr.  |          | mber<br>rative<br>rities<br>ired<br>r<br>osed<br>)<br>: 3, 4 | Expiration (Month/Da                    |                 |  | Amo<br>Secu<br>Unde<br>Deriv | le and<br>unt of<br>rities<br>rlying<br>ative<br>rity (Instr. | Sec<br>(Ins                  | Price of<br>ivative<br>curity<br>str. 5)  | 9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | Owner<br>Form<br>Director Ind<br>(I) (In               | nership<br>n:<br>ct (D)<br>ndirect<br>nstr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
| Explanatio   | n of Respons   | ses:                                       |  | Code                                       | v   | (A)      | (D)  | Dat<br>Exe                              | te<br>ercisable | Expiration<br>e Date   | Title                        | Amount<br>or<br>Number<br>of<br>Shares                        |                              |   |  |  |  |  |
| •  | -  | stock option is CAD5                       | 5.37. The U.S. dollar  | equival                                    | ent of th   | e exerc  | ise pr   | rice is                                 | \$4.1945        | using the Ban  | k of Car                     | ada excha   | nge rat                      | e for De  | cember 9, 202  | 20 (CAD1   | .00 = \$0                                      | 0.7811).   |

- 2. The exercise price of the stock option is CAD7.26. The U.S. dollar equivalent of the exercise price is \$5.6708 using the Bank of Canada exchange rate for December 9, 2020 (CAD1.00 = \$0.7811).
- 3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$53.00 to \$53.95, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 9, 2020 at each separate price.
- 4. The Form 4 originally filed is being amended to correct the inadvertent overstatement of the "Amount of Securities Beneficially Owned Following Reported Transactions" by ten (10) shares in each of the first three rows of Table I, column 5.

## Remarks:

/s/ Daniel Dex, Attorney-in-

01/11/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.